Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

Inclusion Criteria: 1. Able to understand and willing to sign the ICF. 2. Adults 18 years of age or older. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. 4. Life expectancy at least 12 weeks. 5. Adequate organ and bone marrow function. 6. Histologically confirmed diagnosis of invasive CSCC. . Exclusion Criteria: 1. Prior treatment with an agent that blocks the PD-1/PD-L1 pathway. 2. Any investigational drugs received within 4 weeks prior to the first study treatment. 3. Receive the last dose of anti-tumor therapy within 4 weeks before the first dose of study therapy. 4. History of autoimmune disease , present active autoimmune disease or inflammatory diseases 5. Pregnant or nursing females.